



How I Treat Patients with Advanced Cancer Following Chemotherapy and Traditional Medicine (75 Cases)

George Zhu*

Department of Oncology, Tehran University of Medical Science, Iran

Abstract

Objective: Traditional systems of medicine all over the world even traditional medicine and cancer have been using plants and plants products for therapeutic intention. The purpose of this retrospective trial is to assess the clinical efficacy of chemotherapy in conjunction with TCM for a broad variety of cancers.

Methods: 75 patients with available cancers were concluded in the study during September 1993 - May 2018. The sex ratio of male: female was 50:25 respectively. The mean age at onset was 46.9 years (range 10-79 years). All patients were treated with different dosage of various chemotherapy in combination with TCM or traditional medicine alone. The detail prescription of TCM varied among a broad variety of carcinomas (see full text case reports). The criteria of Complete Remission (CR) and/or Partial Remission (PR) is according to the rules where physicians have in common with in clinics.

Results: In 75 cases, the CR was obtained in 33(44%) advanced cancers, a short CR in 11(14.7%) cases, PR in 25(33.3%) cancers, Stable disease in 6 cases. As to approach to the schedule of drug administration, 16 lymphoma obtained CR via COMA (CTX, VCR, MMC, and ADM) regimen and TCM or antibiotics and immunotherapy. Five advanced gastric cancer were successfully treated using MFC and cinobufacini/cantharidin, and TCM. In follow up, one HCC accompanied with colon polyps obtained CR via hepatectomy and targeting oncogenic receptor tyrosine kinase inhibitor sorafenib. Among two lung cancers, one female with metastatic lung cancer was given targeting oncogenic receptor EGFR gefitinib therapy after the combination chemotherapy, which was stable disease for 8+ months. CR can also be achieved in one advanced cholangi carcinoma and one advanced gallbladder cancer through major protocol of TCM and the addition of small dosage of chemotherapy. Thyroid cancer was placed on the primary use of TCM. The crude herbs consisted of *sargassum*, *tangle*, *Oyster (mussels)*, *Poria cocos*, *Ophiopogon japonicus*, *Prunella vulgaris*, *Taraxacum*, *Scrophularia ningpoensis*, *Cremastra appendiculata*, *Trichosanthes Kirilowii*, *Sophora subprostrata*, *Houttuynia cordata*, *Scutellaria barbata d. don* and *Oldenlandia diffusa roxb*. Among those long-term survivors, 31 carcinomas obtained in disease-free survival over 5 years, 20 cancers were survival over 10 years, the longest four patients over 25 years.

Conclusion: In this study, I experienced that a CR was a pivotal influencing factor in those longest survival patients and traditional medicine was also recommended. Downregulating oncogenic receptors may be useful paradigm and perspective in currently the third line setting of clinical target therapy and in rendering our better understanding of cancer biology.

Keywords: Cancer chemotherapy; Traditional medicine; Target therapy

Introduction

Chemotherapy is a major skillful of cancer therapy. One of the most important advances in oncology has been increased acceptance of evidence that most patients with disseminated tumors were settled to the protocol of chemotherapy in conjunction with recent targeting oncogenic receptor [1-14], Traditional Medicine (TCM) and/or adoptive immunotherapy (LAK cells, TIL therapy) [15,16]. The experience in Ugandan children with Hodgkin's disease has been excellent [17] and in a study of 14 adults with stage I and II Hodgkin's disease, mostly clinically staged, 13 patients (93%) achieved CR with combination chemotherapy and all were in CR 11 to 94 months after the completion of treatment [18]. Another, A disease-free survivors of 5 years (56.5% to 59.3% vs. 22% to 24.3%) and 10 years (48.9%) was remarkably higher rate in those breast cancers with stage III following surgery plus chemotherapy than only surgery. More promising, in a large trial of

OPEN ACCESS

*Correspondence:

George Zhu, Department of Oncology,
Tehran University of Medical Science,
Tehran, Iran,

E-mail: sansan4240732@163.com

Received Date: 01 Aug 2018

Accepted Date: 17 Sep 2018

Published Date: 20 Sep 2018

Citation:

Zhu G. How I Treat Patients with
Advanced Cancer Following
Chemotherapy and Traditional Medicine
(75 Cases). *Int J Thyroid Res.* 2018;
1(1): 1001.

Copyright © 2018 George Zhu. This is
an open access article distributed under
the Creative Commons Attribution
License, which permits unrestricted
use, distribution, and reproduction in
any medium, provided the original work
is properly cited.

48 HER2-positive early breast cancer patients, targeting the adjuvant trastuzumab treatment demonstrated highly favorable outcome. Five year overall survival rates and disease-free survival rates were 95.8% and 93.8% respectively [19]. Recently, neratinib was recently approved by FDA for extended adjuvant treatment of ER+/HER2+ breast cancer [20]. Others advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. Systemic chemotherapies and combined regimens are currently available, provide palliation and prolong survival. In particular, high-quality clinical trials on TCM in cancer are generally lacking, except for Kampo medication for Japanese cancer patients [21,22], arsenic trioxide (As₂O₃) in the role of acute promyelocytic leukemia (Zhang TD, 1973; Sun HD, 1992; Zhang P, 1996) [23], and cantharidin in treatment of liver cancer [Yang BY, 1970s; [24]. This paper will attempt to place in proper interpretative review from those patients with cancers under remission in this group.

Material and Methods

An 75 patients with available cancers were concluded in the study during September 1993- May 2017. The sex ratio of male: female was 50:25 respectively. The mean age at onset was 46.9 years ranging from 10 to 79 years. Among age distribution, although there is some uncertain about the type distribution of cancers, it was found 38.1 years as the mean age at onset for lymphoma; 44.0 years for liver cancer, while higher mean age at 60.1 years has been shown in lung cancer in this group. The clinical diagnoses in a broad variety of carcinomas consisted of metastatic nasopharyngeal cancer 5 cases, metastatic breast cancer 4, lung tumors 12, Hepatocellular Carcinoma (HCC) 12, stomach cancer 5, hematological malignancies 25 cases (acute leukemia's FAB M1 type 2, M2 type 1, acute promyelocytic leukemia 1, chronic myeloid leukemia CML 2, chronic lymphocytic leukemia CLL 1, multiple myeloma 2, lymphoma 16), thyroid cancer 2, maxillary sinus carcinoma 1, carcinoma of mandibular sinus 2, laryngeal carcinoma 1, gallbladder cancer 1, cholangiocarcinoma 1, metastatic oral cancer 1, epidermoid carcinoma 1, relapsed vulvar cancer 1 and other metastatic sternal and spinal (T12) tumor 1 respectively. All other benign neoplasias were not statistically included. The basic chemotherapeutic regimen consisted of vincristine (VCR, 1-2mg/wk) cyclophosphamide (CTX, 200-1,000 mg/wk) mitomycin C (MMC, 2-4 mg/wk) and 5-fluorouracil (5-Fu, 250-500 mg/day). In addition, the additional drug adriamycin (ADM, 20 mg/wk) in lymphoma and metastatic breast cancer, demethylcantharidin in liver cancer and cisplatin (DDP) or interleukin-2 (PHA)/gefitinib in lung cancer. The detail prescription of TCM varied among a broad variety of carcinomas (see full text case reports). The criteria of Complete Remission (CR) and/or Partial Remission (PR) is according to the rules where physicians have in common with in clinics. Complete Remission (CR): there was no more tumor or tumor complete regressed in patients for at least 1 month; Partial remission: the tumor decreased by more than 50% in patients for at least 1 month; Stable disease: the tumor decreased by less than 50% or increased by no more than 25% in patients; Disease progression: the tumor increased by more than 25% in patients, or new lesions emerged. The efficacy was evaluated according to the survival time from the day when patients were at onset. The clinical data for liver cancer [25,26] and lung cancer [27,28] were previously described.

Results

In 75 cancers, the rate of Complete Remission (CR) was achieved in 33(44%) advanced cancers. All CR patients with advanced cancers

was survival over 5 years, 18 cancers was survival 10 years. Another, a short CR was obtained in 11(14.7%) advanced cancers, the survival time varied from 20 months to 4 years. PR was obtained in 25(33.3%) patients with a broad variety of carcinoma, while three patients (1 malignant lymphoma, 1 carcinoma of mandibular sinus, 1 metastatic tumor of bone) had survival 12, 18+ and 11+ years respectively, implicating a longer survivor in patients the survival with tumours. Otherwise, stable disease was 6 cases. Basic characteristics of studied population were summarized in table 1.

During the schedule of drug administration, all patients were treated with the different dosage of 1 to 4 courses of various combination chemotherapy in conjunction with traditional medicine. In statistically analysis, one patient with nasopharyngeal cancer, the diplopia and unable version in his eye were recovered to "normal" visual acuity following the combination chemotherapy of VCMF (VCR, CTX, MMC and 5-Fu) plus traditional medicine. A patient with rodent ulcer (8 cm x 5 cm) once obtained complete response as to an approach of 5% Fu of retinoic acid ointment. A short CR was achieved by the protocol of MFC (MMC; 5-Fu; Ara-C/homoharringtonine, CTX) plus cantharidin or cinobufacini drug in 5 advanced gastric cancers. One of them was a long-term survivor for 6 years via mass incision and the combination of MFC with herbs *Scutellaria barbata d. don*.

In view of cancer types, 10 lymphoma was settled to the major protocol of the combination conventional chemotherapy (COMA, VCR, CTX, MMC or ADM) in conjunction with traditional medicine which to relieve the chemotherapeutic toxicity, and reinforced the efficacy of chemotherapy. One lymphoma was regressed only by prednisone (200#). Another 4 patients with thumb lymphadenopathy was treated by the use of antibiotics regimen in full dose with anti-inflammatory herbal tablets or immunotherapy lymphocyte transfer factor.

In 12 HCC, 6 HCC were treated mainly by 5-Fu (500-1,000 mg/day) and TCM. Two patients obtained CR through cantharidin and traditional medicine. The main protocol of TCM with adjuvant antibiotics regimen and low dose of dexamethasone was given in a primary liver cancer (AFP+, ascites +++, jaundice +++, liver tumor 3.2 cm x 3.0 cm). One acute promyelocytic leukemia complicated with metastatic liver cancer (7 cm x 4.5 cm) was in CR with all-trans retinoic acid (ATRA) and TCM. The detail prescription of TCM was mentioned before [25,26]. In the follow up, one HCC accompanied with colon polyps obtained complete remission via hepatectomy and targeting oncogenic receptor tyrosine kinase inhibitor sorafenib.

Dose intensity has proven to be critical in maximizing chemotherapeutic efficacy for numerous human cancers. Eight other patients with cancers were in remission through small dosage of chemotherapy and TCM or traditional medicine (TCM) alone. There were 4 lung cancers, 1 gallbladder cancer, 1 cholangiocarcinoma and 2 thyroid cancers. Among targeting two metastatic lung cancers, one female with lung cancer was given the combination chemotherapy plus targeting oncogenic receptor EGFRv III gefitinib, which was stable disease for 8+ months. Thyroid cancer was placed on the primary use of traditional medicine. The crude herbs consisted of *sargassum*, *tangle*, *Oyster (mussels)*, *Poria cocos*, *Ophiopogon japonicus*, *Prunella vulgaris*, *Taraxacum*, *Scrophularia ningpoensis*, *Cremastra appendiculata*, *Trichosanthes Kirilowii*, *Sophora subprostrata*, *Houttuynia cordata*, *Scutellaria barbata d. don* and *Oldenlandia diffusa roxb*.

Table 1: Patients characteristics.

Cancer types	Cases No	Sex	Mean ages(years)	Treatment Protocol	Response following therapy	Duration of remission (years) <1 1-3 >3-5 >5-10 >10
lymphoma	16	M14, F2	38.1(13-66)	COMA(10) [·] , Radiotherapy [·] (1), prednisone(1), Immunotherapy(4)	CR(10) [·] , short CR(2), PR(4)	1 3 2 1 9
HCC	12	M10, F2	44.0(26-63)	a.5-Fu (250-1,000mg/day), VCR, CTX, MMC, TCM b. Cantharidin, TCM c. hepatectomy, sorafenib	CR(8), Short CR(2), PR(1), stable disease(1)	1 4 1 3 3
Lung tumors	12	M8,F4	60.1(40-79)	a. COMF, TCM; b. DDP, etoposide, gefitinib c. CTX,5-FU, antitumor capsule; d. TCM alone	CR(2), short CR(2), PR(3), stable disease(5)	4 3 3 1
NPC	5	M3, F2	51.4(38-75)	a. VCMF, TCM b.CTX,5-FU,TCM	CR(1), short CR(1), PR(3)	1 3 1
MBC	4	F4	31.3(25-41)	a. COMF, TCM b.COP, TCM	CR(3),PR(1)	1 2
Stomach cancer	5	M2, F3	42.3(35-50)	a.MFC, TCM; b.CTX,5-FU,antitumor capsule	CR(1), short CR(2), PR(2)	1 3 1
AML	3	M2, F1	4,18,20	DA [·] , HA, TCM	PR(3)	3
APL	1	M	31	ATRA 80mg/day; H 1mg x 5 days; TCM	CR	1
CML	2	M1, F1	33,62	Busulfan, TCM	CR(1), short CR(1)	1 1
CLL	1	M	58	Chlorambucil, TCM	CR	1 died of stomach cancer
MM	2	M1, F1	60,63	Thalidomide, pred, TCM	Short CR(1), PR(1)	1
Epidermoid cancer	1	F	72	5% FU of retinoic acid ointment	PR	1
Thyroid cancer	2	F2	54,60	TCM alone	CR(2)	1
bile cancer	1	F	65	CTX, 5-FU,TCM	CR	1
Cholangio-carcinoma	1	M	72	MFC (MMC, 5-FU, CTX), TCM	CR	1 died of intestinal cancer
Others [·]	7	M5,F2	57.5(44-69)	COFP, COMMB, TCM	CR(1), PR(6)	1 2 1 3

Note: HCC: Hepatocellular Carcinoma; NPC: Metastatic Nasopharyngeal Cancer; MBC: Metastatic Breast Cancer; AML: Acute Myeloid Leukemia; APL: Acute Promyelocytic Leukemia; CML: Chronic Myeloid Leukemia; CLL: Chronic Lymphocytic Leukemia; MM: Multiple Myeloma; COMA:CTX, VCR, MMC, ADM; COMF: CTX, VCR, MMC/ADM, 5-FU; VCMF: VCR, CTX, MMC/DDP; 5-FU; COP: CTX, VCR, pred; COFP: CTX, VCR, 5-FU, PHA, Pred; DA: DNR, 45 mg/m², Ara-c 100 mg/m²; HA: Homoharringtone 1mg x 5days, ara-c 50 mg, intramuscle, twice a day; MFC: MMC, 5-FU, Ara-c/H, CTX; COMMB: CTX, VCR, MMC, MTX, Bleomycin; ATRA: All-Trans Retinoic Acid; Pred: prednisone; TCM: Traditional Medicine; M: Male; F: Female; ·: Cases Number; ·: Treatment in Another Hospital; ·: Include Oral Cancer 1, Relapsed Vulva Cancer 1, Laryngeal Cancer 1, Maxillary Sinus Carcinoma 1, Carcinoma Of Mandibular Sinus 2 and Metastatic Bone Tumor 1

The survival times in those patients with remission were less than 1 years 10 cases, 1 to 3 years 20 cases, over 3 to 5 years 12 cases, over 5 to 10 years 11 cases, over 10 to 20 years 13 cases, and over 20 years 7 cases. In differential types of 20 patients with over 10 year's survivors, lymphoma occupied 8 cases (40%). Among 7 patients with over 20 years, lymphoma occupied 3 cases, metastatic breast cancer 2 cases and hepatocellular carcinoma 2 cases.

Discussion

In this study, a series of the long follow up of patients with cancers were reported. I experienced that a CR was a pivotal influencing factor in those longest survival patients, and traditional medicine was also recommended. The traditional combination chemotherapy program for lymphomas of favorable histologic type has been CVP (CTX, VCR, Pred) given at 21-days intervals [29]. Cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) were used in the NCI study for patients with nodular mixed and nodular histocytic lymphomas [30]. More intensive CVP programs with the addition of Adriamycin or bleomycin, or both, known as BACOP or CHOP-bleo, resulted in overall complete remission rates for patients with diffuse lymphomas ranging from 48% to 89% [31-34]. The NCI program of this 5-drug program, complete remission rates with this approach has

ranged from 48% to 94% [33]. In this study, the CR rates was 63% in 16 lymphomas, 6 CR were used by CVP or COMA regimens.

The use of chemotherapy to treat stomach cancer has no firmly established standard of care [35]. Some drugs used in stomach cancer treatment have included: 5-Fu (fluorouracil), doxorubicin (Adriamycin), mitomycin C and most recently oxaliplatin, irinotecan in various combination. The relative benefits of these different drugs, alone or in combination, are unclear [36]. There are evidence supporting that clinical researches are exploring the benefits of giving chemotherapy as adjuvant therapy for surgery to destroy remaining cancer cells [37]. In recent analyses of definitive surgery followed by adjuvant radio chemotherapy (5-Fu/leucovorin LV regimens) for patients with gastric cancer, Liu and Ahmed [38] reported that 59.3% (48/81) patients survived >3 years, 18.5% (15/81) patients survived 5 or more years. Eighteen out of 81(22.2%) patients are still alive with a medium survival of 142 months (57-196 months). In this study, 5 patients with gastric cancer obtained a short CR through MFC regimen plus cinobufacini and cantharidin drugs. One relapsed gastric cancer survived over 6 years after surgery and adjuvant chemotherapy. More recent, treatment with HER2 inhibitor, trastuzumab, has been demonstrated to improve overall survival in inoperable locally

advanced or metastatic gastric carcinoma overexpressing the HER2 [37]. Oncogenic receptor HER2 [39] is overexpressed in 13% to 22% of patients with gastric cancer [40,41]. Tanz et al. [42] reported two HER2-positive metastatic gastric adenocarcinoma who favorably responded to second line chemotherapy (FOLFIRI, irinotecan plus 5-Fu) with trastuzumab continuation following progressive disease to first line treatment containing trastuzumab, implicating trastuzumab continuation in metastatic HER positive gastric cancer is safe, practical and improve survival.

Oncogenic EGFR mutations are found in 10% to 35% of lung adenocarcinomas, with predominants in a subset of patients with Non-Small Cell Lung Cancer (NSCLC) [43-49]. These mutations, which commonly occur as either small in-frame deletions in exon 19 or point mutations T790M or L858R in exon 21 within the EGFR tyrosine kinase domain, confer constitutive activity and sensitivity to EGFR tyrosine kinase inhibitor (TKI) [49,50]. Konduri et al. [51] reported five patients with metastatic lung cancer whose tumors harbored EGFR fusion, most commonly RAD5, are recurrent in lung cancer. Four of whom were treated with EGFR TKI erlotinib with documented antitumor response for 5, 6, 8 and 20 months respectively. An early EGFR TKI trial randomized patients with EGFR mutation positive stage III b or IV adenocarcinoma to treatment with afatinib or gemcitabine and cisplatin, treatment with afatinib prolonged progression free survival to 11.0 months as opposed to 5.6 months with gemcitabine and cisplatin [7]. In a total of 65 lung cancers with EGFR-mut (exon 19 del/L858R, no T790M), after INC 280 plus gefitinib, Partial Remission (PRs) were obtained in 12/65 evaluable patients (ORR 18%) and 40/65(62%) patients had stable disease [52]. Central Nervous System (CNS) metastases are common in patients with Non-Small-Cell Lung Cancer (NSCLC). Osimertinib has shown systemic efficacy in patients with CNS metastases, and early clinical evidence shows efficacy in the CNS. In the phase II trials of 50 patients with T790M-positive advanced NSCLC, confirmed CNS ORR (Objective Response Rate) and DCR (Disease Control Rate) were 54% (27/50) and 92% (46/50) respectively. Median follow-up for CNS PFS (progression-free survival) was 11 months. Osimertinib (80 mg) demonstrated clinically meaningful efficacy against CNS metastases [53]. In the phase III trial of 419 patients with advanced T790M positive NSCLC with osimertinib vs. platinum based therapy, progression free survival in the osimertinib group was 8.5 months, compared to the platinum-based therapy group at 4.2 months [6]. Targeting oncogenic ALK inhibitors Crizotinib (250 mg, twice a day) [54], and Alectinib (600 mg, orally twice daily, second-generation ALK inhibitor, better efficacy and better tolerability) also prevented lung cancer progression and delayed the time to brain metastases according to the results of the phase III ALEX trial presented at the 2017 ASCO Annual Meeting [55]. Serra [56] reported the clinical response of a lapatinib-based therapy in lung metastatic lesions of a Li-Fraumeni syndrome patient with oncogenic HER2V659E mutation and an EGFR-exon 20 insertion. A symptomatic and radiologic clinical response was achieved using oral daily lapatinib at a dose of 1,000 mg in combination with intravenous weekly paclitaxel 80 mg/m², latelty, trastuzumab initial dose of 8 mg/kg intravenously, and then followed by 6 mg/kg every three weeks. In total, the clinical benefits lasted over 9 months. In Cuba, Cima Vax-EGF, promising, an active vaccine targeting EGF as the major ligand of oncogenic EGFR, it is in use as a cancer therapy against non-small cell lung cancer (NSCLC) [57,58]. In this study, we use gefitinib in keeping stable disease for 8+ months in a woman with lung adenocarcinoma,

and using gefitinib in more patients are under investigation.

References

- Zhu G, Saboor-Yaraghi AA, Yarden Y, Santos J, Neil JC. Downregulating oncogenic receptor: From bench to clinic. *Hematol Med Oncol*. 2016;1:30-40.
- Zhu G, Saboor-Yaraghi AA, Yarden Y. Targeting oncogenic receptor: from molecular physiology to currently the standard of target therapy. *Advance Pharmaceutical Journal*. 2017;2:10-28.
- van den Heuvel CNAM, Das AI, de Bitter T, Simmer F, Wurdinger T. Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes. *Scientific Reports*. 2018;8:7072.
- Toledo RA, Garralda E, Mitsi M, Pons T, Monsech J, Vega E, et al. Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of anti-angiogenic therapies. *Clin Cancer Res*. 2018;24(15):3550-9.
- Cross DA, Ashton SE, Ghiorghlu S, Eherlein C, Nebhan C, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discov*. 2014;4(9):1046-61.
- Conterato AJ, Belanger AR, Yarmus LB, Akulian JA. Update on NSCLC tissue acquisition, processing, and profiling in the molecular age. *Hematology Med Oncology*. 2017;2:1-8.
- Pai SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alteration. *Cancer Discov*. 2018;8(7):812-21.
- Liu J, Sareddy GR, Zhou M, Viswanadhappalli S, Li X, Zhao Lai, et al. Differential effects of estrogen receptor beta isoforms on glioblastoma progression. *Cancer Res*. 2018.
- Weir HM, Bradbury RH, Lawson M, Rabow AA, Butter D, Callis RJ, et al. AZD9496. An oral estrogen receptor inhibitor that block the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. *Cancer Res*. 2016;76:3307-18.
- Went DC, Kocherginsky M, Tonsing-Carter EY, Dolcen N, Hosfield DJ, Lastra RR, et al. Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer. *Clin Cancer Res*. 2018;24(14):3433-46.
- Reddy JA, Allagadda VM, Leamon CP. Targeting therapeutic and imaging agents to folate receptor positive tumors. *Curr Pharm Biotechnol*. 2005;6(2):131-50.
- Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, et al. Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients. *Clin Cancer Res*. 2018;24(13):3014-25.
- Zhu G, Saboor-Yaraghi A, Dharmadhikari D, Baer J. A pilot study of chemotherapy and traditional plant medicine in hematology malignancy: report of thirty-four cases. *Hematology Med Oncology*. 2017;22:
- Zhu G. EpCAM-an old cancer antigen, turned oncogenic receptor and its targeting immunotherapy. *Universal J Pharmaceutic Res*. 2018;32:43-8.
- Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic cancer. *N Engl J Med*. 1985;313(23):1485-92.
- Forget MA, Haymakere C, Hess KR, Meng YJ, Creasy C, Tatiana Karpinet V, et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. *Clin Cancer Res*. 2018.

17. Olweny CLM, Katongole-Mbidde E, Mirre C, Lwanga SK, Magrath I, Ziegler JL. Childhood Hodgkin's disease in Uganda: a ten-year experience. *Cancer*. 1978;42(2):787-92.
18. Launa F, Baccarani M, Fiacchini M. Combination chemotherapy in stage I or II Hodgkin's disease. *Lancet*. 1979;2:1072-3.
19. Kato M, Sakuyama A, Matsutani T, Minato H. Efficacy of Trastuzumab therapy in HER2-positive early breast cancer patients in our clinic. *Proceedings of BIT's 8th Annual World Cancer Congress*. 2015;301.
20. Singh H, Walker AJ, Amiri-Kordestani L, Cheng J, Tang S, Balcazar P, et al. US Food and Drug Administration Approval: Neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. *Clin Cancer Res*. 2018;24(15):3486-91.
21. Takeda T, Yamaguchi T, Yaegashi N. "perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines". *Int J Clin Oncol*. 2012;17(2):143-9.
22. Ito A, Munakata K, Imazu Y, Watanabe K. First nationwide attitude survey of Japanese physicians on the use of traditional Japanese medicine (Kampo) in cancer treatment. *Evidence-Based Complementary and Alternative Medicine*. 2012.
23. Zhu G. Novel treatment of acute promyelocytic leukemia: As2O3, retinoic acid and retinoid pharmacology. *Curr Phar Biotechnol*. 2013;14(9):849-58.
24. Zhang Q, Zhu G. The pathological pattern of seven malignant cancers following Demethylcantharidin. *Advance Pharmaceutical Journal*. 2017;2(6):243-7.
25. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E. Treatment of advanced Hepatocellular Carcinoma (HCC) with the combined protocol of chemotherapy 5-fluorouracil and traditional medicine: report of ten cases. *J Clin Trials Pathol Case Stud*. 2017;22:61-5.
26. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E. Role of traditional herbal medicine in the treatment of advanced Hepatocellular Carcinoma (HCC): past and future ongoing. *Advance Pharmaceutical Journal*. 2017;23:115-20.
27. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E, Baer J. A pilot study of lung cancer following chemotherapy and traditional medicine: report of 12 cases. *Lungs and Breathing*. 2017;13:1-4.
28. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E, Baer J. Clinical trials of lung cancer after chemotherapy and traditional medicine (12 cases). *Advance Pharmaceutical Journal*. 2017;25:199-203.
29. Bonadonna G, Lattuada A, Monfardini S, et al. Combined radiotherapy-chemotherapy in localized non-Hodgkin's lymphomas: five-year results of a randomized study. In *Adjuvant Therapy of Cancer II*. Edited by Jones SE, Salmon SE. Grune & Stratton, New York, 1979;145-53.
30. Anderson T, Bender RA, Fisher RI, DeVita VT, Chabner BA, Berard CW, et al. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term follow up. *Cancer Treat Rep*. 1977;61:1057-66.
31. Skarin AT, Rosenthal DS, Moloney WC, Frei E 3rd. Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, Adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). *Blood*. 1977;49(5):759-70.
32. Rodriguez V, Cabanillas F, Burgess MA, McKelvey EM, Valdivieso M, Bodey GP, et al. Combination chemotherapy ('CHOP-bleo') in advanced (non-Hodgkin's) malignant lymphoma. *Blood*. 1977;49:325-33.
33. Schein PS, De Vita VT, Hubbard S, Chabner BA, Canellos GP, Berard C, et al. Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. *Ann Intern Med*. 1976;85:417-22.
34. Case DC Jr. Combination chemotherapy of advanced diffuse non-Hodgkin's lymphoma: results of cyclophosphamide, Adriamycin, vincristine, prednisone and bleomycin (CHOP-bleo). *J Maine Med Assoc*. 1979;70:348-52.
35. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Haerting J, et al. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev*. 2017;(3):CD004064.
36. Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S. Chemotherapy for advanced gastric cancer: across the years for a standard of care. *Expert Opin Pharmacother*. 2007;8(6):797-808.
37. Oritura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Maria Maddalena, et al. Treatment of gastric cancer. *World J Gastroenterol*. 2014;20(7):1635-49.
38. Liu JL, Ahme S. Long term survival of patients with gastric cancer treated with adjuvant radio-chemotherapy: proposal of a prognostic index with implication for treatment modification. *Oncology Research and Reviews (ORR)*. 2018;1(2):1-5.
39. Skrypek N, Vasseur R, Vincent A, Duchêne B, Van Seuningen I, Jonckheere N. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecin/ SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug resistance associated protein MRP-2. *Oncotarget*. 2015;6(13):10853-67.
40. Meza-Junco J, Au HJ, Sawyer MB. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. *Cancer Manag Res*. 2011;3:57-64.
41. Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. *Mod Pathol*. 2013;26(6):816-24.
42. Tanz R, Mahfoud T, Alami EI, Bazine A, Errihani H, Ichou M. Is there any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer? report of two cases and literature review. *Hematology & Medical Oncology*. 2018;3(2).
43. Gabitova L, Gorin A, Astsurov I. Molecular pathways:sterols and receptor signaling in cancer. *Clin Cancer Res*. 2014;20(1):28-34.
44. Shimizu N, Kondo I. Hyperproduction of EGF receptor in human A431 cell is regulated by a translocation chromosome, t(7;11)(p22;q23). *Cytogenetics and Cell Genetics*. 1982;32:316-317.
45. Merlino GT, Xu YH, Ishii S, Clark AJ, Semba K, Toyoshima K, et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. *Science*. 1984;224(4647):417-9.
46. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature*. 1984;309(5967):418-25.
47. Miltra S, Han S, Soderstram K, Wong A. Preferential expression of an oncogenic receptor in brain tumor stem cells:identification and targeting using an engineered antibody. In: *Proc Am Assoc Cancer Res*. *Cancer. Res p72*.
48. Hembrough T, Thyparambil S, Liao WL, Darfler M, Krizman D. Quantitative multiplexed SRM analysis of oncogenic receptors in FFPE colorectal carcinoma tissue. *AACR 103rd Annual Meeting Chicago, IL*. *Cancer Res*. 2012;72:5537.
49. Lee JC, Vivanco I, Beroukheim R, Huang JH, Feng WL, DeBiasi RM, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in extracellular domain. *PLoS Med*. 2006;3(12):e485.
50. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd, et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. *Cancer Res*. 2007;67(15):7319-26.
51. Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlize BJ, Gowen K, et al. EGFR fusions as Novel Therapeutic Targets in Lung Cancer. *Cancer Discov*. 2016;6(6):601-11.

52. Wu YL, Kim DW, Felip E, Zhang L, Liu X, Zhou CC, et al. Phase II safety and efficacy results of a single-arm phase II study of capmatinib (INC 280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2016;34(15):9020.
53. Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, et al. CNS response to Osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. *Ann Oncol*. 2018;29(3):687-93.
54. Shun Lu, Tony Mok, You Lu, Jianying Zhou, Yuankai Shi, Virote Sriuranpong. Phase 3 study of first-line crizotinib vs pemetrexed/cisplatin or carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2016;34(15):9058.
55. Alice Tsang Shaw, Solange Peters, Tony Mok, Shirish M. Gadgeel, Jin Seok Ahn, Sai-Hong Ignatius Ou. Alectinib versus Crizotinib in treatment-naive advanced ALK positive non-small cell lung cancer (NSCLC): primary results of the Global Phase III ALEX Study. *J Clin Oncol*. 2017;35(18):LBA9008.
56. Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, et al. Clinical response to a lapatinib-based therapy in a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. *Cancer Discov*. 2013;3(11):1238-44.
57. Rodriguez PC, Rodriguez C, Gonzalez G, Lage A. Clinical development and perspective of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. *MEDICC Rev*. 2010;12(1):17-23.
58. Gonzalez G, Crombet T, Lage A. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment. *Curr Cancer Drug Targets*. 2011;11(1):103-10.